Genetic polymorphism at BCL2 as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma.

ABSTRACT:

SUBMITTER: Bashash M 

PROVIDER: S-EPMC5477624 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature